Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Demadex, Soaanz. Every FDA application for this active ingredient: 3 branded and 12 generic.
As of Nov 15, 2026, FDA lists 15 applications for Torsemide (sold as Demadex, Soaanz), first approved Aug 23, 1993, with 3 new uses approved and 1 published complete response letter.
First approved: Aug 23, 1993
Applications: 15
New uses approved: 3
Complete response letters: 1
Medicare spending, 2025: $63.0M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Roche
Teva
Strides Pharma Intl
Hikma
Aurobindo Pharma
Sun Pharm Inds